Literature DB >> 33817315

Knockdown of TUG1 rescues cardiomyocyte hypertrophy through targeting the miR-497/MEF2C axis.

Guorong Zhang1, Xinghua Ni2.   

Abstract

The aim of this study was to investigate the detailed role and molecular mechanism of long noncoding RNA (lncRNA) taurine upregulated gene 1 (TUG1) in cardiac hypertrophy. Cardiac hypertrophy was established by transverse abdominal aortic constriction (TAC) in vivo or angiotensin II (Ang II) treatment in vitro. Levels of lncRNA TUG1, miR-497 and myocyte enhancer factor 2C (MEF2C) mRNA were assessed by quantitative reverse transcriptase PCR (qRT-PCR). Western blot assay was performed to determine the expression of MEF2C protein. The endogenous interactions among TUG1, miR-497 and MEF2C were confirmed by dual-luciferase reporter and RNA immunoprecipitation assays. Our data indicated that TUG1 was upregulated and miR-497 was downregulated in the TAC rat model and Ang II-induced cardiomyocytes. TUG1 knockdown or miR-497 overexpression alleviated the hypertrophy induced by Ang II in cardiomyocytes. Moreover, TUG1 acted as a sponge of miR-497, and MEF2C was directly targeted and repressed by miR-497. miR-497 overexpression mediated the protective role of TUG1 knockdown in Ang II-induced cardiomyocyte hypertrophy. MEF2C was a functional target of miR-497 in regulating Ang II-induced cardiomyocyte hypertrophy. In addition, TUG1 regulated MEF2C expression through sponging miR-497. Knockdown of TUG1 rescued Ang II-induced hypertrophy in cardiomyocytes at least partly through targeting the miR-497/MEF2C axis, highlighting a novel promising therapeutic target for cardiac hypertrophy treatment.
© 2021 Guorong Zhang and Xinghua Ni, published by De Gruyter.

Entities:  

Keywords:  TUG1; cardiac hypertrophy; miR-497; myocyte enhancer factor 2C

Year:  2021        PMID: 33817315      PMCID: PMC7968548          DOI: 10.1515/biol-2021-0025

Source DB:  PubMed          Journal:  Open Life Sci        ISSN: 2391-5412            Impact factor:   0.938


  40 in total

Review 1.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

Authors:  Bianca C Bernardo; Kate L Weeks; Lynette Pretorius; Julie R McMullen
Journal:  Pharmacol Ther       Date:  2010-05-12       Impact factor: 12.310

2.  Long noncoding RNA TUG1 promotes cardiac fibroblast transformation to myofibroblasts via miR‑29c in chronic hypoxia.

Authors:  Yun Zhu; Zezhou Feng; Zhao Jian; Yingbin Xiao
Journal:  Mol Med Rep       Date:  2018-07-27       Impact factor: 2.952

3.  The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miR-101.

Authors:  Lili Xiao; Yulei Gu; Yunlong Sun; Jun Chen; Xiaofang Wang; Yanzhou Zhang; Lu Gao; Ling Li
Journal:  J Cell Physiol       Date:  2019-01-03       Impact factor: 6.384

Review 4.  Molecular targets and regulators of cardiac hypertrophy.

Authors:  Agrawal Rohini; Neeraj Agrawal; Chintan N Koyani; Randhir Singh
Journal:  Pharmacol Res       Date:  2009-12-05       Impact factor: 7.658

Review 5.  Physiological and pathological cardiac hypertrophy.

Authors:  Ippei Shimizu; Tohru Minamino
Journal:  J Mol Cell Cardiol       Date:  2016-06-02       Impact factor: 5.000

6.  The long noncoding RNA XIST protects cardiomyocyte hypertrophy by targeting miR-330-3p.

Authors:  Yuewu Chen; Xianxia Liu; Lei Chen; Weiwei Chen; Yuansheng Zhang; Jiaxian Chen; Xuezheng Wu; Yong Zhao; Xiaoyan Wu; Guowei Sun
Journal:  Biochem Biophys Res Commun       Date:  2018-10-05       Impact factor: 3.575

Review 7.  Non-Coding RNAs Including miRNAs and lncRNAs in Cardiovascular Biology and Disease.

Authors:  Masaharu Kataoka; Da-Zhi Wang
Journal:  Cells       Date:  2014-08-22       Impact factor: 6.600

8.  Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy.

Authors:  Chun-Mei Tang; Fang-Zhou Liu; Jie-Ning Zhu; Yong-Heng Fu; Qiu-Xiong Lin; Chun-Yu Deng; Zhi-Qin Hu; Hui Yang; Xi-Long Zheng; Jian-Ding Cheng; Shu-Lin Wu; Zhi-Xin Shan
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

9.  MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in mice.

Authors:  Ana Helena M Pereira; Carolina F M Z Clemente; Alisson C Cardoso; Thais H Theizen; Silvana A Rocco; Carla C Judice; Maria Carolina Guido; Vinícius D B Pascoal; Iscia Lopes-Cendes; José Roberto M Souza; Kleber G Franchini
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

10.  The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy.

Authors:  Zhihua Wang; Xiao-Jing Zhang; Yan-Xiao Ji; Peng Zhang; Ke-Qiong Deng; Jun Gong; Shuxun Ren; Xinghua Wang; Iris Chen; He Wang; Chen Gao; Tomohiro Yokota; Yen Sin Ang; Shen Li; Ashley Cass; Thomas M Vondriska; Guangping Li; Arjun Deb; Deepak Srivastava; Huang-Tian Yang; Xinshu Xiao; Hongliang Li; Yibin Wang
Journal:  Nat Med       Date:  2016-09-12       Impact factor: 53.440

View more
  1 in total

1.  Interactions between the ERK1/2 signaling pathway and PCAF play a key role in PE‑induced cardiomyocyte hypertrophy.

Authors:  Qian Mao; Shuqi Wu; Chang Peng; Bohui Peng; Xiaomei Luo; Lixin Huang; Huanting Zhang
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.